人福医药(600079.SH)：屈螺酮炔雌醇片获得药品注册证书

Core Viewpoint - The company, Renfu Pharmaceutical, announced that its subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., Ltd., has received the drug registration certificate for Drospirenone and Ethinyl Estradiol Tablets from the National Medical Products Administration, indicating a new product launch in the contraceptive market [1]. Group 1 - Renfu Pharmaceutical's subsidiary, Jiulong Renfu, holds 100% ownership by another subsidiary, Hubei Gedian Renfu Pharmaceutical Co., Ltd. [1] - The newly approved drug, Drospirenone and Ethinyl Estradiol Tablets, is intended for female contraception [1].